Dyax (NASDAQ: DYAX) and Zosano Pharma (NASDAQ:ZSAN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Dyax and Zosano Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyax 0 0 0 0 N/A
Zosano Pharma 0 0 2 0 3.00

Zosano Pharma has a consensus target price of $3.50, suggesting a potential upside of 503.45%. Given Zosano Pharma’s higher possible upside, analysts plainly believe Zosano Pharma is more favorable than Dyax.

Institutional & Insider Ownership

19.7% of Zosano Pharma shares are held by institutional investors. 3.0% of Zosano Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Dyax and Zosano Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dyax -47.32% -14.86% -12.09%
Zosano Pharma N/A -169.79% -94.28%

Earnings & Valuation

This table compares Dyax and Zosano Pharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dyax N/A N/A N/A ($0.21) -181.14
Zosano Pharma $310,000.00 73.83 -$29.83 million ($1.17) -0.50

Dyax has higher earnings, but lower revenue than Zosano Pharma. Dyax is trading at a lower price-to-earnings ratio than Zosano Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Zosano Pharma beats Dyax on 6 of the 9 factors compared between the two stocks.

About Dyax

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

About Zosano Pharma

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Receive News & Ratings for Dyax Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyax Corp. and related companies with MarketBeat.com's FREE daily email newsletter.